利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.025 秒)

    Influenza inhibiting compositions and methods
    2.
    发明申请
    Influenza inhibiting compositions and methods 有权
    流感抑制组合物和方法

    公开(公告)号：US20100152109A1

    公开(公告)日：2010-06-17

    申请号：US12452240

    申请日：2008-06-25

    申请人： Robert F. Garry ,  Russell B. Wilson

    发明人： Robert F. Garry ,  Russell B. Wilson

    IPC分类号： A61K38/16 ,  C07K14/11 ,  C07K7/06 ,  C07K7/08 ,  C07K16/08 ,  A61K38/08 ,  A61K38/10

    CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K38/04 ,  A61K38/10 ,  A61K39/00 ,  A61K39/145 ,  C07K7/06 ,  C07K7/08 ,  C12N2760/00033 ,  C12N2760/16122 ,  C12N2760/16134

    摘要： The present invention provides peptides, peptide analogs, peptide derivatives and pharmaceutical compositions useful for treating or preventing influenza infections or preventing the person-to-person transmission of an influenza infection. A peptide of the invention comprises an influenza virus-cell fusion inhibiting portion of the fusion initiation region (FIR) of a wild-type influenza hemagglutinin 2 protein or a variant thereof. In a preferred embodiment, a peptide of the invention consists of 8 to 40 consecutive amino acid residues a portion of a wild-type influenza hemagglutinin 2 protein or a variant thereof, the portion of the protein comprising the FIR of the protein and up to five amino acid residues on the amino-terminal and carboxy-terminal sides of the FIR.

    摘要翻译： 本发明提供了可用于治疗或预防流感感染或预防流感感染的个人间传播的肽，肽类似物，肽衍生物和药物组合物。 本发明的肽包含野生型流感血凝素2蛋白的融合起始区（FIR）的流感病毒 - 细胞融合抑制部分或其变体。 在优选的实施方案中，本发明的肽由野生型流感血凝素2蛋白或其变体的一部分的8至40个连续氨基酸残基组成，蛋白质的部分蛋白质包含蛋白质的FIR和至多5个 在FIR的氨基末端和羧基末端侧的氨基酸残基。

    Influenza inhibiting compositions and methods
    3.
    发明申请
    Influenza inhibiting compositions and methods 有权
    流感抑制组合物和方法

    公开(公告)号：US20090234096A1

    公开(公告)日：2009-09-17

    申请号：US12378561

    申请日：2009-02-17

    申请人： Robert F. Garry ,  Russell B. Wilson

    发明人： Robert F. Garry ,  Russell B. Wilson

    IPC分类号： C07K14/11 ,  C07K7/06 ,  C07K7/08

    CPC分类号： C07K14/005 ,  A61K38/00 ,  C12N2760/16122

    摘要： The present invention provides compositions useful for treating or preventing influenza infections. The composition comprises an isolated polypeptide including a sequence of at least 8 contiguous amino acid residues of the fusion initiation region (FIR) of an influenza hemagglutinin 2 protein or a peptide analog of the sequence. The FIR is a segment of the full length hemagglutinin 2 protein which is bounded by an amino-terminal region within the amino-terminal alpha-helix thereof and a carboxy terminus within the carboxy-terminal alpha-helix thereof, with a cysteine loop therebetween. The amino-terminal region of the FIR comprises a portion of the final 10 to 20 amino acid residues of the amino-terminal alpha-helix of the hemagglutinin 2 protein, and includes 3 or 4 hydrophobic amino acid residues, a positively-charged amino acid residue, a negatively-charged amino acid residue, and an aromatic amino acid residue. The carboxy terminus of the FIR is the carboxy terminus of the first peptide sequence of the hemagglutinin 2 protein beyond the amino terminal helix, which exhibits a positive Wimley-White interfacial hydrophobicity.

    摘要翻译： 本发明提供了可用于治疗或预防流感感染的组合物。 该组合物包含分离的多肽，其包含流感血凝素2蛋白质的融合起始区域（FIR）的至少8个连续氨基酸残基的序列或序列的肽类似物。 FIR是全长血凝素2蛋白质的一段，其由其氨基末端α-螺旋内的氨基末端区域和羧基末端α-螺旋内的羧基末端界定，其间具有半胱氨酸环。 FIR的氨基末端区域包含血凝素2蛋白的氨基末端α-螺旋的最后10至20个氨基酸残基的一部分，并且包括3或4个疏水性氨基酸残基，带正电荷的氨基酸 残基，带负电荷的氨基酸残基和芳香族氨基酸残基。 FIR的羧基末端是超过氨基末端螺旋的血凝素2蛋白的第一个肽序列的羧基末端，其表现出Wimley-White阳性的界面疏水性。

    Influenza inhibiting compositions and methods
    4.
    发明授权
    Influenza inhibiting compositions and methods 有权
    流感抑制组合物和方法

    公开(公告)号：US08222204B2

    公开(公告)日：2012-07-17

    申请号：US12378561

    申请日：2009-02-17

    申请人： Robert F. Garry ,  Russell B. Wilson

    发明人： Robert F. Garry ,  Russell B. Wilson

    IPC分类号： A61K38/04 ,  C07K7/08

    CPC分类号： C07K14/005 ,  A61K38/00 ,  C12N2760/16122

    摘要： The present invention provides compositions useful for treating or preventing influenza infections. The composition comprises an isolated polypeptide including a sequence of at least 8 contiguous amino acid residues of the fusion initiation region (FIR) of an influenza hemagglutinin 2 protein or a peptide analog of the sequence. The FIR is a segment of the full length hemagglutinin 2 protein which is bounded by an amino-terminal region within the amino-terminal alpha-helix thereof and a carboxy terminus within the carboxy-terminal alpha-helix thereof, with a cysteine loop therebetween. The amino-terminal region of the FIR comprises a portion of the final 10 to 20 amino acid residues of the amino-terminal alpha-helix of the hemagglutinin 2 protein, and includes 3 or 4 hydrophobic amino acid residues, a positively-charged amino acid residue, a negatively-charged amino acid residue, and an aromatic amino acid residue. The carboxy terminus of the FIR is the carboxy terminus of the first peptide sequence of the hemagglutinin 2 protein beyond the amino terminal helix, which exhibits a positive Wimley-White interfacial hydrophobicity.

    摘要翻译： 本发明提供了可用于治疗或预防流感感染的组合物。 该组合物包含分离的多肽，其包含流感血凝素2蛋白质的融合起始区域（FIR）的至少8个连续氨基酸残基的序列或序列的肽类似物。 FIR是全长血凝素2蛋白质的一段，其由其氨基末端α-螺旋内的氨基末端区域和羧基末端α-螺旋内的羧基末端界定，其间具有半胱氨酸环。 FIR的氨基末端区域包含血凝素2蛋白的氨基末端α-螺旋的最后10至20个氨基酸残基的一部分，并且包括3或4个疏水性氨基酸残基，带正电荷的氨基酸 残基，带负电荷的氨基酸残基和芳香族氨基酸残基。 FIR的羧基末端是超过氨基末端螺旋的血凝素2蛋白的第一个肽序列的羧基末端，其表现出Wimley-White阳性的界面疏水性。

    Influenza inhibiting compositions and methods
    5.
    发明授权
    Influenza inhibiting compositions and methods 有权
    流感抑制组合物和方法

    公开(公告)号：US08604165B2

    公开(公告)日：2013-12-10

    申请号：US12452240

    申请日：2008-06-25

    申请人： Robert F. Garry ,  Russell B. Wilson

    发明人： Robert F. Garry ,  Russell B. Wilson

    IPC分类号： A61K38/04 ,  C07K7/08 ,  C12N1/00

    CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K38/04 ,  A61K38/10 ,  A61K39/00 ,  A61K39/145 ,  C07K7/06 ,  C07K7/08 ,  C12N2760/00033 ,  C12N2760/16122 ,  C12N2760/16134

    摘要： The present invention provides peptides, peptide analogs, peptide derivatives and pharmaceutical compositions useful for treating or preventing influenza infections or preventing the person-to-person transmission of an influenza infection. A peptide of the invention comprises an influenza virus-cell fusion inhibiting portion of the fusion initiation region (FIR) of a wild-type influenza hemagglutinin 2 protein or a variant thereof. In a preferred embodiment, a peptide of the invention consists of 8 to 40 consecutive amino acid residues a portion of a wild-type influenza hemagglutinin 2 protein or a variant thereof, the portion of the protein comprising the FIR of the protein and up to five amino acid residues on the amino-terminal and carboxy-terminal sides of the FIR.

    摘要翻译： 本发明提供了可用于治疗或预防流感感染或预防流感感染的个人间传播的肽，肽类似物，肽衍生物和药物组合物。 本发明的肽包含野生型流感血凝素2蛋白的融合起始区（FIR）的流感病毒 - 细胞融合抑制部分或其变体。 在优选的实施方案中，本发明的肽由野生型流感血凝素2蛋白或其变体的一部分的8至40个连续氨基酸残基组成，蛋白质的部分蛋白质包含蛋白质的FIR和至多5个 在FIR的氨基末端和羧基末端侧的氨基酸残基。